文献速递核素与放射性配体治疗肿瘤 PET/CT神经核医学

肽受体放射性核素治疗使转移性胰岛素瘤完全缓解

Complete Resolution of Disease After Peptide Receptor Radionuclide Therapy in a Patient of Metastatic Insulinoma.
PubMed 文献 · Clin Nucl Med · 2022-01-01

本文报道一例48岁男性转移性胰岛素瘤患者,肝转移经动脉化疗栓塞失败后接受多周期177Lu-DOTATATE肽受体放射性核素治疗,68Ga-DOTATATE PET/CT显示完全形态学和代谢缓解。顽固性低血糖发作消退,生活质量显著改善。肽受体放射性核素治疗对常规治疗失败的转移性胰岛素瘤是有前景的靶向治疗。

要点

  • 177Lu-DOTATATE PRRT后68Ga-DOTATATE PET/CT示完全形态学和代谢缓解。
  • 顽固性低血糖发作消退,生活质量显著改善。
  • 常规治疗失败的转移性胰岛素瘤可考虑PRRT。

核心结论

  • 肽受体放射性核素治疗可使常规治疗失败的转移性胰岛素瘤患者获得完全形态学和代谢缓解,并改善生活质量。

研究设计与样本

  • 单例病例报告:48岁男性转移性胰岛素瘤患者,肝转移经动脉化疗栓塞失败后接受多周期177Lu-DOTATATE治疗。

主要发现

  • 68Ga-DOTATATE PET/CT显示完全形态学和代谢缓解。
  • 顽固性低血糖发作在治疗后消退,生活质量显著改善。

临床怎么用

  • 对常规治疗失败的转移性胰岛素瘤,肽受体放射性核素治疗是可考虑的靶向治疗选择。

局限性

  • 单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 48-year-old man, a case of metastatic insulinoma, who failed transarterial chemoembolization of liver metastases underwent multiple cycles of peptide receptor radionuclide therapy with 177Lu-DOTATATE, following which a complete morphologic and metabolic response was demonstrated on 68Ga-DOTATATE PET/CT. Patient had a remarkable improvement in his quality of life as intractable hypoglycemic episodes resolved after treatment. Peptide receptor radionuclide therapy is a promising targeted radionuclide therapy in patients of metastatic insulinomas that can result in reduced tumor burden and improved quality of life, particularly those who fail the conventional treatment modalities as seen in the present case.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Verma P, Malhotra G, Dodamani MH, et al. Complete Resolution of Disease After Peptide Receptor Radionuclide Therapy in a Patient of Metastatic Insulinoma. Clin Nucl Med. 2022. PMID: 34284474. doi:10.1097/RLU.0000000000003831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。